Unbiased Analysis of Today's Healthcare Issues

IVI Model highlights ACR Conference

Written By: Jason Shafrin - Nov• 06•17

As reported in a Academy of Managed Care & Specialty Pharmacy newsletter, titled “Mathematical Model Aims to Improve Cost-Effectiveness of Rheumatology Treatment“, the Innovation and Value Initiative’s is highlighted from the American College of Rheumatology conference.  Here is an excerpt:

Biological therapies for moderate to severe rheumatoid arthritis have significantly improved treatment and prognosis. However, the high cost of treatment may be a barrier to access. Researchers led by Devin Incerti, a health economist and data scientist at the Innovation and Value Initiative in Oakland, Calif., are developing a cost-effectiveness mathematical model to align prices with value. They shared their latest findings with attendees at the 2017 annual meeting of the American College of Rheumatology (ACR) and the Association of Rheumatology Health Professionals (ARHP).

In their abstract titled, “Open-Source Consensus-Based Models to Improve the Cost-Effectiveness of Rheumatology Care,” the authors said the literature lacks consensus on such models, and that estimates of treatment value vary widely. In addition, they said, because new evidence regarding biologics is being generated rapidly, any model that estimates value must continually evolve and update as well. They called for “transparent, flexible, and accessible cost-effectiveness models that shed light on the implications of different modeling approaches.”

The researchers developed an open-source set of cost-effectiveness models and made it publicly available on GitHub and as an R package. They also created a web application where users can run the model online, modifying their own parameter values and structural assumptions. They then applied a number of different plausible modeling assumptions to their model to compare the cost-effectiveness of a standard sequence of six biologic treatments to conventional disease-modifying antirheumatic drugs (cDMARDs).

Certainly an exciting, new approach to measuring treatment value in RA.

You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

Leave a Reply

Your email address will not be published. Required fields are marked *